imatinib Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 1423 152459-95-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • imatinib
  • gleevec
  • imatinib mesylate
  • imatinib mesilate
  • CGP-57-148B
  • CGP57148B
  • CGP-57148
  • CGP57148
  • STI-571
  • STI571
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
  • Molecular weight: 493.62
  • Formula: C29H31N7O
  • CLOGP: 4.38
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 86.28
  • ALOGS: -4.53
  • ROTB: 7

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
May 10, 2001 FDA NOVARTIS

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 2590.16 25.64 1294 9438 151030 3224097
Neoplasm malignant 1401.28 25.64 388 10344 8009 3367118
Chronic myeloid leukaemia 1266.15 25.64 245 10487 857 3374270
Gastrointestinal stromal tumour 1231.33 25.64 217 10515 370 3374757
Malignant neoplasm progression 1168.62 25.64 402 10330 17391 3357736
Blast crisis in myelogenous leukaemia 1099.20 25.64 182 10550 159 3374968
Nausea 1098.83 25.64 705 10027 128940 3246187
Drug resistance 961.93 25.64 255 10477 4408 3370719
Diarrhoea 892.64 25.64 572 10160 103776 3271351
Pleural effusion 869.92 25.64 328 10404 18451 3356676
Anaemia 815.53 25.64 430 10302 53903 3321224
Vomiting 742.46 25.64 482 10250 89049 3286078
Pyrexia 712.49 25.64 453 10279 80662 3294465
Oedema peripheral 681.93 25.64 329 10403 34032 3341095
Haemoglobin decreased 677.51 25.64 315 10417 29979 3345148
Rash 670.46 25.64 415 10317 70406 3304721
Muscle spasms 668.32 25.64 301 10431 26602 3348525
Second primary malignancy 655.80 25.64 151 10581 1396 3373731
Dyspnoea 625.87 25.64 458 10274 102476 3272651
Thrombocytopenia 614.15 25.64 309 10423 34959 3340168
Fatigue 606.82 25.64 457 10275 106783 3268344
Periorbital oedema 582.21 25.64 136 10596 1346 3373781
Pancytopenia 579.07 25.64 245 10487 18575 3356552
Fluid retention 532.75 25.64 184 10548 7974 3367153
Leukaemia recurrent 502.59 25.64 102 10630 478 3374649
White blood cell count decreased 455.55 25.64 226 10506 24721 3350406
Platelet count decreased 455.22 25.64 233 10499 27235 3347892
Gene mutation identification test positive 449.07 25.64 74 10658 60 3375067
Oedema 444.23 25.64 189 10543 14491 3360636
Neoplasm progression 428.24 25.64 140 10592 5104 3370023
Chromosome analysis abnormal 423.24 25.64 69 10663 48 3375079
Bone marrow failure 405.65 25.64 152 10580 8335 3366792
Ascites 405.15 25.64 156 10576 9221 3365906
Neutropenia 401.67 25.64 229 10503 33157 3341970
Abdominal pain 376.47 25.64 247 10485 45978 3329149
Blood creatinine increased 375.58 25.64 190 10542 21628 3353499
Asthenia 372.29 25.64 281 10451 65384 3309743
Metastases to liver 368.38 25.64 117 10615 3879 3371248
Drug intolerance 360.44 25.64 153 10579 11645 3363482
Disease progression 342.20 25.64 204 10528 32055 3343072
Neoplasm recurrence 325.03 25.64 74 10658 645 3374482
Drug ineffective 322.57 25.64 331 10401 115759 3259368
Pneumonia 317.52 25.64 263 10469 69880 3305247
White blood cell count increased 316.76 25.64 143 10589 12617 3362510
Eye swelling 293.93 25.64 105 10627 5012 3370115
Face oedema 292.60 25.64 105 10627 5079 3370048
Myalgia 286.94 25.64 182 10550 31893 3343234
Malaise 281.61 25.64 238 10494 64939 3310188
Exposure during pregnancy 281.00 25.64 170 10562 27393 3347734
Sepsis 273.00 25.64 177 10555 32196 3342931
Haematocrit decreased 264.21 25.64 108 10624 7459 3367668
Gastric antral vascular ectasia 258.02 25.64 49 10683 149 3374978
Eyelid oedema 257.67 25.64 86 10646 3339 3371788
Decreased appetite 244.48 25.64 182 10550 41308 3333819
Bone pain 244.09 25.64 110 10622 9651 3365476
Surgery 242.11 25.64 99 10633 6841 3368286
Pericardial effusion 237.47 25.64 94 10638 5967 3369160
Splenomegaly 237.05 25.64 79 10653 3052 3372075
General physical health deterioration 233.26 25.64 136 10596 20453 3354674
Red blood cell count decreased 229.81 25.64 93 10639 6255 3368872
Therapeutic response decreased 228.28 25.64 108 10624 10590 3364537
Renal failure 224.78 25.64 158 10574 32782 3342345
Arthralgia 220.08 25.64 201 10531 60660 3314467
Generalised oedema 219.52 25.64 77 10655 3478 3371649
Aspartate aminotransferase increased 217.06 25.64 131 10601 20982 3354145
Alanine aminotransferase increased 215.89 25.64 136 10596 23504 3351623
Blood lactate dehydrogenase increased 214.35 25.64 89 10643 6391 3368736
Blood alkaline phosphatase increased 208.32 25.64 101 10631 10452 3364675
Acute lymphocytic leukaemia recurrent 205.16 25.64 46 10686 371 3374756
Pain in extremity 204.67 25.64 176 10556 49036 3326091
Abdominal pain upper 204.43 25.64 134 10598 24782 3350345
Headache 196.75 25.64 229 10503 91751 3283376
Pruritus 195.76 25.64 168 10564 46665 3328462
Cardiac failure 191.94 25.64 119 10613 19986 3355141
Weight increased 188.73 25.64 131 10601 26609 3348518
Treatment failure 187.17 25.64 81 10651 6443 3368684
Swelling face 180.46 25.64 94 10638 11322 3363805
Cough 176.80 25.64 148 10584 39710 3335417
Graft versus host disease 172.04 25.64 59 10673 2488 3372639
Weight decreased 171.86 25.64 146 10586 39965 3335162
Gastrointestinal haemorrhage 171.02 25.64 119 10613 24255 3350872
Chronic myeloid leukaemia recurrent 169.75 25.64 29 10703 36 3375091
Leukocytosis 169.22 25.64 73 10659 5760 3369367
Infection 166.58 25.64 119 10613 25283 3349844
Leukopenia 164.67 25.64 99 10633 15724 3359403
Abdominal distension 162.50 25.64 93 10639 13483 3361644
Blood bilirubin increased 161.72 25.64 85 10647 10424 3364703
Therapy non-responder 159.47 25.64 85 10647 10724 3364403
Prostate cancer 159.28 25.64 62 10670 3758 3371369
Ejection fraction decreased 157.81 25.64 63 10669 4084 3371043
Platelet count increased 155.89 25.64 59 10673 3312 3371815
Chronic myeloid leukaemia transformation 155.41 25.64 28 10704 57 3375070
Respiratory failure 153.08 25.64 109 10623 23032 3352095
Pain 149.19 25.64 176 10556 71381 3303746
Rash generalised 147.33 25.64 78 10654 9704 3365423
Abdominal discomfort 146.19 25.64 98 10634 18786 3356341
Dehydration 145.14 25.64 123 10609 33526 3341601
Blood urea increased 142.09 25.64 70 10662 7490 3367637
Interstitial lung disease 141.45 25.64 86 10646 13930 3361197
Cardiac failure congestive 138.95 25.64 114 10618 29708 3345419
Normal newborn 138.44 25.64 44 10688 1457 3373670
Chest pain 135.62 25.64 128 10604 40147 3334980
Stem cell transplant 134.72 25.64 38 10694 827 3374300
Exposure via father 134.21 25.64 35 10697 560 3374567
Blood creatine phosphokinase increased 131.71 25.64 80 10652 12933 3362194
Conjunctival haemorrhage 127.67 25.64 39 10693 1130 3373997
Multiple organ dysfunction syndrome 124.20 25.64 80 10652 14330 3360797
Hepatitis 123.42 25.64 69 10663 9556 3365571
C-reactive protein increased 122.32 25.64 68 10664 9315 3365812
Premature baby 121.14 25.64 62 10670 7191 3367936
Metastases to peritoneum 120.61 25.64 32 10700 549 3374578
Lung disorder 120.02 25.64 66 10666 8851 3366276
Neutrophil count decreased 119.23 25.64 69 10663 10204 3364923
Subdural haematoma 115.90 25.64 52 10680 4503 3370624
Hepatotoxicity 115.34 25.64 55 10677 5476 3369651
Swelling 115.19 25.64 85 10647 18959 3356168
Gait disturbance 113.90 25.64 99 10633 27893 3347234
Chloroma 113.38 25.64 23 10709 107 3375020
Acute lymphocytic leukaemia 112.80 25.64 33 10699 821 3374306
Blast cell crisis 112.37 25.64 22 10710 82 3375045
Jaundice 112.31 25.64 66 10666 10041 3365086
Pulmonary oedema 112.31 25.64 70 10662 11841 3363286
Bone marrow transplant 111.91 25.64 28 10704 376 3374751
Septic shock 110.85 25.64 70 10662 12114 3363013
Skin exfoliation 109.58 25.64 60 10672 7977 3367150
Febrile neutropenia 108.75 25.64 82 10650 18893 3356234
Dyspnoea exertional 106.76 25.64 56 10676 6830 3368297
Gamma-glutamyltransferase increased 105.10 25.64 61 10671 9067 3366060
Renal impairment 104.84 25.64 79 10653 18182 3356945
Disseminated intravascular coagulation 103.40 25.64 53 10679 6164 3368963
Acute kidney injury 103.05 25.64 122 10610 49561 3325566
Recurrent cancer 102.21 25.64 27 10705 455 3374672
Blast cells present 101.62 25.64 21 10711 109 3375018
Blast cell count increased 101.16 25.64 24 10708 254 3374873
Lung infiltration 99.25 25.64 45 10687 3993 3371134
Hypoxia 99.12 25.64 60 10672 9631 3365496
Thrombocytosis 98.36 25.64 33 10699 1299 3373828
Lymphadenopathy 96.64 25.64 55 10677 7877 3367250
Hepatic failure 96.40 25.64 61 10671 10591 3364536
Mucosal inflammation 96.31 25.64 55 10677 7928 3367199
Gastric cancer 95.90 25.64 34 10698 1582 3373545
Tumour haemorrhage 95.31 25.64 28 10704 707 3374420
Cytogenetic analysis abnormal 94.45 25.64 18 10714 56 3375071
Liver disorder 93.65 25.64 59 10673 10164 3364963
Haematotoxicity 93.14 25.64 36 10696 2138 3372989
Tumour necrosis 92.75 25.64 23 10709 297 3374830
Skin lesion 92.33 25.64 47 10685 5386 3369741
Hypokalaemia 91.15 25.64 65 10667 13740 3361387
Cardiomyopathy 90.72 25.64 45 10687 4881 3370246
Constipation 90.65 25.64 91 10641 30721 3344406
Erythema 90.15 25.64 88 10644 28722 3346405
Atrial fibrillation 90.03 25.64 81 10651 23860 3351267
Colon cancer 89.92 25.64 39 10693 3113 3372014
Drug interaction 88.97 25.64 110 10622 46702 3328425
Growth retardation 88.58 25.64 27 10705 776 3374351
Neuropathy peripheral 88.33 25.64 69 10663 16738 3358389
Cerebral haemorrhage 88.09 25.64 56 10676 9798 3365329
Tumour excision 87.59 25.64 19 10713 129 3374998
Lacrimation increased 87.44 25.64 39 10693 3329 3371798
Maternal exposure during pregnancy 85.96 25.64 56 10676 10215 3364912
Liver function test abnormal 85.77 25.64 61 10671 12840 3362287
Gastrectomy 85.14 25.64 20 10712 202 3374925
Alopecia 85.06 25.64 71 10661 18915 3356212
Blindness 84.90 25.64 45 10687 5604 3369523
Blister 84.01 25.64 52 10680 8682 3366445
Cerebrovascular accident 83.83 25.64 93 10639 35195 3339932
Acute myeloid leukaemia 82.84 25.64 43 10689 5130 3369997
Chronic graft versus host disease 82.31 25.64 28 10704 1150 3373977
Transaminases increased 82.27 25.64 47 10685 6777 3368350
Depression 81.33 25.64 97 10635 39673 3335454
Gene mutation 81.33 25.64 20 10712 249 3374878
Metastasis 81.29 25.64 30 10702 1567 3373560
Abortion spontaneous 81.08 25.64 55 10677 10730 3364397
Joint swelling 81.03 25.64 66 10666 16991 3358136
Visual impairment 80.73 25.64 61 10671 14085 3361042
Peripheral swelling 79.98 25.64 64 10668 16068 3359059
Eye haemorrhage 79.88 25.64 31 10701 1861 3373266
Back pain 79.87 25.64 94 10638 37911 3337216
Dizziness 79.53 25.64 135 10597 76377 3298750
Myelodysplastic syndrome 79.30 25.64 43 10689 5604 3369523
Bone marrow oedema 79.00 25.64 19 10713 214 3374913
Muscular weakness 78.80 25.64 70 10662 20271 3354856
Visual acuity reduced 77.53 25.64 50 10682 8964 3366163
Myocardial infarction 76.39 25.64 99 10633 44034 3331093
Exposure via body fluid 76.25 25.64 21 10711 417 3374710
Haemorrhage 76.07 25.64 68 10664 19853 3355274
Cytogenetic abnormality 75.83 25.64 21 10711 426 3374701
Metastases to lung 75.26 25.64 32 10700 2432 3372695
Hypoaesthesia 73.96 25.64 74 10658 24865 3350262
Respiratory distress 73.31 25.64 47 10685 8341 3366786
Eye oedema 73.01 25.64 21 10711 491 3374636
Blood uric acid increased 72.64 25.64 27 10705 1439 3373688
Palpitations 72.59 25.64 65 10667 19018 3356109
Breast cancer 72.22 25.64 46 10686 8071 3367056
Melaena 71.51 25.64 44 10688 7268 3367859
Gastrooesophageal reflux disease 70.24 25.64 52 10680 11639 3363488
Chills 70.24 25.64 68 10664 21954 3353173
Cardiac disorder 69.22 25.64 55 10677 13664 3361463
Vision blurred 69.18 25.64 64 10668 19525 3355602
Dysphagia 69.01 25.64 64 10668 19587 3355540
Hepatomegaly 68.66 25.64 32 10700 3023 3372104
Myelofibrosis 68.03 25.64 22 10710 770 3374357
Gastrointestinal disorder 68.01 25.64 49 10683 10520 3364607
Renal disorder 67.68 25.64 42 10690 7042 3368085
Hepatic enzyme increased 67.42 25.64 54 10678 13571 3361556
Aspiration pleural cavity 67.42 25.64 17 10715 236 3374891
Tumour lysis syndrome 67.15 25.64 29 10703 2290 3372837
Eosinophil count increased 66.81 25.64 28 10704 2053 3373074
Acute respiratory distress syndrome 66.80 25.64 39 10693 5855 3369272
Marrow hyperplasia 66.07 25.64 17 10715 257 3374870
Blood albumin decreased 65.94 25.64 31 10701 2987 3372140
Ileus 65.90 25.64 34 10698 4005 3371122
CD4 lymphocytes increased 65.60 25.64 14 10718 87 3375040
Computerised tomogram abnormal 64.97 25.64 21 10711 734 3374393
Drug level increased 64.90 25.64 35 10697 4510 3370617
Central nervous system leukaemia 64.53 25.64 13 10719 58 3375069
Complications of transplant surgery 64.21 25.64 16 10716 211 3374916
Neoplasm 63.97 25.64 26 10706 1763 3373364
Chronic kidney disease 63.87 25.64 39 10693 6353 3368774
Dry skin 63.76 25.64 42 10690 7801 3367326
Rash erythematous 63.18 25.64 42 10690 7920 3367207
Eosinophilia 62.62 25.64 35 10697 4838 3370289
Toxicity to various agents 62.59 25.64 93 10639 46961 3328166
Atelectasis 62.23 25.64 31 10701 3391 3371736
Haematochezia 61.96 25.64 40 10692 7181 3367946
Hypertension 61.47 25.64 83 10649 38383 3336744
Hepatic necrosis 61.13 25.64 25 10707 1722 3373405
Fall 59.94 25.64 103 10629 58780 3316347
Pneumonitis 59.82 25.64 37 10695 6166 3368961
Bladder cancer 58.80 25.64 27 10705 2465 3372662
Dyspepsia 58.48 25.64 47 10685 11865 3363262
Hepatic lesion 57.34 25.64 20 10712 886 3374241
Musculoskeletal pain 56.60 25.64 47 10685 12419 3362708
Diabetes mellitus 55.62 25.64 46 10686 12087 3363040
Ocular hyperaemia 55.51 25.64 33 10699 5120 3370007
Gastritis 55.36 25.64 36 10696 6541 3368586
Lichen planus 54.76 25.64 17 10715 520 3374607
Lung neoplasm malignant 54.49 25.64 33 10699 5295 3369832
Abortion induced 54.32 25.64 29 10703 3662 3371465
Flatulence 53.58 25.64 34 10698 5925 3369202
Blood glucose increased 53.42 25.64 55 10677 19100 3356027
Metastases to lymph nodes 52.67 25.64 21 10711 1354 3373773
Cardiomegaly 52.61 25.64 30 10702 4308 3370819
Blood potassium decreased 51.70 25.64 34 10698 6296 3368831
Therapy responder 51.66 25.64 14 10718 261 3374866
Productive cough 51.50 25.64 34 10698 6337 3368790
Haematemesis 51.47 25.64 35 10697 6850 3368277
Caesarean section 51.42 25.64 30 10702 4496 3370631
Bronchopulmonary aspergillosis 51.41 25.64 23 10709 1976 3373151
Inflammation 51.14 25.64 36 10696 7449 3367678
Pseudoporphyria 51.10 25.64 12 10720 121 3375006
Bone marrow necrosis 51.05 25.64 11 10721 72 3375055
Papilloedema 50.86 25.64 20 10712 1243 3373884
Dialysis 50.75 25.64 29 10703 4180 3370947
Metastases to bone 50.60 25.64 26 10706 3035 3372092
Post embolisation syndrome 50.39 25.64 9 10723 17 3375110
Hepatic function abnormal 50.29 25.64 42 10690 11185 3363942
Trisomy 8 50.05 25.64 9 10723 18 3375109
Dilatation ventricular 49.61 25.64 19 10713 1100 3374027
Hypotension 49.57 25.64 86 10646 49428 3325699
Biopsy bone marrow abnormal 49.49 25.64 13 10719 214 3374913
Pulmonary hypertension 48.44 25.64 33 10699 6477 3368650
Intra-abdominal haemorrhage 48.10 25.64 17 10715 783 3374344
Bone marrow disorder 47.97 25.64 16 10716 618 3374509
Disease recurrence 47.40 25.64 30 10702 5204 3369923
Acute graft versus host disease 47.19 25.64 21 10711 1781 3373346
Concomitant disease progression 46.58 25.64 17 10715 860 3374267
Lichenoid keratosis 46.58 25.64 15 10717 518 3374609
Skin ulcer 46.33 25.64 30 10702 5410 3369717
Urine output decreased 46.15 25.64 23 10709 2518 3372609
Chest X-ray abnormal 46.14 25.64 18 10714 1095 3374032
Confusional state 46.12 25.64 72 10660 37926 3337201
Lung adenocarcinoma 46.00 25.64 18 10714 1104 3374023
Amnesia 45.72 25.64 39 10693 10687 3364440
Amylase increased 45.60 25.64 22 10710 2244 3372883
Dysgeusia 45.59 25.64 40 10692 11384 3363743
Brain oedema 45.30 25.64 26 10706 3778 3371349
Chest discomfort 45.27 25.64 48 10684 17237 3357890
Leukaemia 45.12 25.64 19 10713 1409 3373718
Rales 45.06 25.64 20 10712 1686 3373441
Mass 44.70 25.64 22 10710 2344 3372783
Urinary tract infection 44.64 25.64 64 10668 31264 3343863
Premature labour 44.48 25.64 21 10711 2042 3373085
Haematuria 44.09 25.64 37 10695 9915 3365212
Hepatic steatosis 44.05 25.64 28 10704 4892 3370235
Myositis 43.68 25.64 22 10710 2463 3372664
Depressed level of consciousness 43.47 25.64 39 10693 11426 3363701
Hyperbilirubinaemia 43.41 25.64 24 10708 3247 3371880
Skin disorder 42.75 25.64 27 10705 4666 3370461
Aplasia 42.67 25.64 15 10717 680 3374447
Rash pruritic 42.53 25.64 35 10697 9129 3365998
Staphylococcal infection 42.42 25.64 34 10698 8545 3366582
Aphasia 42.29 25.64 31 10701 6830 3368297
Blood sodium decreased 42.21 25.64 27 10705 4769 3370358
Abdominal mass 42.19 25.64 14 10718 532 3374595
Hepatic neoplasm 42.01 25.64 15 10717 712 3374415
Cholestasis 41.97 25.64 28 10704 5309 3369818
Hypothyroidism 41.80 25.64 29 10703 5860 3369267
Pancreatitis 41.71 25.64 42 10690 14203 3360924
Lipase increased 41.62 25.64 22 10710 2721 3372406
Hepatitis B 41.19 25.64 21 10711 2412 3372715
Conjunctivitis 41.07 25.64 22 10710 2796 3372331
Hypoalbuminaemia 40.94 25.64 21 10711 2443 3372684
Lung neoplasm 40.68 25.64 18 10714 1506 3373621
Drug eruption 40.57 25.64 27 10705 5098 3370029
Polyserositis 40.26 25.64 10 10722 130 3374997
Iron deficiency anaemia 40.06 25.64 21 10711 2554 3372573
Multiple-drug resistance 39.97 25.64 12 10720 327 3374800
Squamous cell carcinoma 39.76 25.64 21 10711 2593 3372534
Hypoglycaemia 39.71 25.64 41 10691 14277 3360850
Oxygen saturation decreased 39.60 25.64 35 10697 10056 3365071
Endotracheal intubation 39.47 25.64 15 10717 850 3374277
Rash papular 39.34 25.64 23 10709 3459 3371668
Peritonitis 38.97 25.64 26 10706 4929 3370198
Pigmentation disorder 38.74 25.64 16 10716 1130 3373997
Pulmonary haemorrhage 38.69 25.64 21 10711 2740 3372387
Lethargy 38.63 25.64 40 10692 13975 3361152
Insomnia 38.08 25.64 64 10668 35834 3339293
Skin hyperpigmentation 37.85 25.64 16 10716 1198 3373929
Rectal haemorrhage 37.81 25.64 33 10699 9325 3365802
Condition aggravated 37.76 25.64 67 10665 39166 3335961
Product use issue 37.65 25.64 42 10690 15959 3359168
Gait inability 37.58 25.64 30 10702 7495 3367632
Wheezing 37.49 25.64 31 10701 8140 3366987
Feeling abnormal 37.42 25.64 55 10677 27470 3347657
Rash maculo-papular 37.27 25.64 27 10705 5840 3369287
Blood pressure decreased 37.26 25.64 39 10693 13797 3361330
Treatment noncompliance 37.06 25.64 32 10700 8913 3366214
Intestinal perforation 37.00 25.64 21 10711 2987 3372140
Blood blister 36.94 25.64 13 10719 591 3374536
Allogenic bone marrow transplantation therapy 36.92 25.64 7 10725 21 3375106
Viral infection 36.88 25.64 27 10705 5935 3369192
Parakeratosis 36.75 25.64 9 10723 110 3375017
Hepatic mass 36.70 25.64 11 10721 298 3374829
Cataract 36.68 25.64 29 10703 7147 3367980
Acquired gene mutation 36.66 25.64 8 10724 56 3375071
Hypophagia 36.48 25.64 27 10705 6034 3369093
Paralysis 36.46 25.64 20 10712 2664 3372463
Gastrointestinal toxicity 36.28 25.64 15 10717 1062 3374065
Hyponatraemia 36.20 25.64 44 10688 18315 3356812
Dermatitis exfoliative 36.05 25.64 20 10712 2723 3372404
Low birth weight baby 36.00 25.64 17 10715 1653 3373474
Paraesthesia 35.95 25.64 54 10678 27494 3347633
Hypoacusis 35.75 25.64 24 10708 4596 3370531
Lymphocyte count decreased 35.58 25.64 23 10709 4136 3370991
Peritoneal haemorrhage 35.53 25.64 13 10719 662 3374465
Splenectomy 35.47 25.64 11 10721 335 3374792
Hepatic cirrhosis 35.16 25.64 23 10709 4219 3370908
Echocardiogram abnormal 34.95 25.64 11 10721 352 3374775
Stomatitis 34.80 25.64 35 10697 11817 3363310
Skin fragility 34.62 25.64 9 10723 142 3374985
Skin atrophy 34.61 25.64 13 10719 713 3374414
Pulmonary fibrosis 34.58 25.64 23 10709 4339 3370788
Macular degeneration 34.57 25.64 16 10716 1487 3373640
Eye pain 34.31 25.64 26 10706 6021 3369106
Mitral valve incompetence 34.25 25.64 22 10710 3912 3371215
Heart rate increased 34.04 25.64 38 10694 14448 3360679
Cholangitis 33.53 25.64 16 10716 1593 3373534
Skin mass 33.51 25.64 15 10717 1290 3373837
Myocardial ischaemia 33.46 25.64 24 10708 5110 3370017
Dysphonia 33.45 25.64 28 10704 7476 3367651
Acute leukaemia 33.42 25.64 12 10720 579 3374548
Eczema 33.30 25.64 22 10710 4104 3371023
Slit-lamp tests abnormal 33.29 25.64 5 10727 0 3375127
Bronchitis 33.28 25.64 38 10694 14807 3360320
Thrombosis 33.18 25.64 37 10695 14053 3361074
Product use in unapproved indication 32.85 25.64 21 10711 3705 3371422
Agranulocytosis 32.73 25.64 24 10708 5288 3369839
Desmoid tumour 32.60 25.64 7 10725 45 3375082
Tuberculosis 32.40 25.64 19 10713 2874 3372253
Respiratory disorder 32.33 25.64 25 10707 5965 3369162
Adenocarcinoma 32.32 25.64 12 10720 637 3374490
Renal cell carcinoma 32.11 25.64 17 10715 2109 3373018
Blood disorder 32.07 25.64 15 10717 1427 3373700
Metastases to central nervous system 31.98 25.64 19 10713 2944 3372183
Dementia 31.95 25.64 21 10711 3883 3371244
Dermatitis bullous 31.81 25.64 17 10715 2149 3372978
Tricuspid valve incompetence 31.67 25.64 18 10714 2567 3372560
Pleurisy 31.62 25.64 16 10716 1808 3373319
Nervous system disorder 31.60 25.64 23 10709 5010 3370117
Hemiplegia 31.58 25.64 17 10715 2181 3372946
Hyperkeratosis 31.41 25.64 14 10718 1192 3373935
Glaucoma 31.22 25.64 18 10714 2638 3372489
Loss of consciousness 30.94 25.64 51 10681 28096 3347031
Refractory cancer 30.83 25.64 7 10725 60 3375067
Retinal haemorrhage 30.72 25.64 17 10715 2303 3372824
Protein total decreased 30.48 25.64 14 10718 1278 3373849
Blood iron decreased 30.38 25.64 14 10718 1288 3373839
Pneumatosis intestinalis 30.36 25.64 12 10720 756 3374371
Polyneuropathy 30.30 25.64 17 10715 2365 3372762
Pancreatic carcinoma 30.22 25.64 18 10714 2801 3372326
Pleural fibrosis 30.13 25.64 10 10722 380 3374747
Malnutrition 30.12 25.64 18 10714 2818 3372309
Cytopenia 30.11 25.64 14 10718 1314 3373813
Anuria 29.80 25.64 18 10714 2873 3372254
Exposure via partner 29.77 25.64 7 10725 71 3375056
Concomitant disease aggravated 29.75 25.64 13 10719 1055 3374072
Gastric haemorrhage 29.69 25.64 19 10713 3357 3371770
Hepatic encephalopathy 29.69 25.64 19 10713 3358 3371769
Intervertebral disc protrusion 29.67 25.64 20 10712 3856 3371271
Photophobia 29.62 25.64 18 10714 2904 3372223
Febrile bone marrow aplasia 29.56 25.64 13 10719 1072 3374055
Mouth ulceration 29.42 25.64 21 10711 4439 3370688
Hyperuricaemia 29.38 25.64 14 10718 1389 3373738
Petechiae 29.33 25.64 18 10714 2956 3372171
Hypogammaglobulinaemia 29.24 25.64 13 10719 1100 3374027
Graft versus host disease in gastrointestinal tract 29.11 25.64 10 10722 423 3374704
Obliterative bronchiolitis 28.93 25.64 10 10722 431 3374696
Thyroid cancer 28.84 25.64 13 10719 1136 3373991
Graft versus host disease in skin 28.82 25.64 10 10722 436 3374691
Congestive cardiomyopathy 28.78 25.64 15 10717 1803 3373324
Laryngeal oedema 28.62 25.64 15 10717 1823 3373304
Colitis 28.54 25.64 25 10707 7096 3368031
Night sweats 28.42 25.64 21 10711 4682 3370445
Pneumothorax 28.29 25.64 20 10712 4164 3370963
Skin fissures 28.26 25.64 14 10718 1512 3373615
Haemorrhage intracranial 28.20 25.64 22 10710 5317 3369810
Chronic graft versus host disease in skin 28.18 25.64 7 10725 91 3375036
Hepatic fibrosis 28.15 25.64 12 10720 917 3374210
Right ventricular failure 28.07 25.64 17 10715 2726 3372401
Mental disorder 28.06 25.64 23 10709 5964 3369163
Hyperglycaemia 28.05 25.64 27 10705 8641 3366486
Blood test abnormal 28.04 25.64 14 10718 1538 3373589
Hepatosplenomegaly 27.97 25.64 12 10720 932 3374195
Pleuritic pain 27.94 25.64 12 10720 934 3374193
Tachycardia 27.94 25.64 44 10688 23327 3351800
Eating disorder 27.87 25.64 17 10715 2762 3372365
Body temperature increased 27.78 25.64 21 10711 4845 3370282
Haemoptysis 27.72 25.64 24 10708 6707 3368420
Glomerular filtration rate decreased 27.56 25.64 16 10716 2375 3372752
Orthopnoea 27.56 25.64 12 10720 966 3374161
Oral pain 27.52 25.64 19 10713 3809 3371318
Skin hypopigmentation 27.49 25.64 8 10724 195 3374932
Myopathy 27.42 25.64 17 10715 2842 3372285
Cancer surgery 27.42 25.64 8 10724 197 3374930
Foetal death 27.39 25.64 15 10717 1991 3373136
Activated partial thromboplastin time prolonged 27.31 25.64 16 10716 2416 3372711
Foetal exposure during pregnancy 27.03 25.64 35 10697 15516 3359611
Acanthosis 26.95 25.64 7 10725 110 3375017
Escherichia infection 26.93 25.64 14 10718 1674 3373453
Necrosis 26.83 25.64 14 10718 1686 3373441
Pneumonia aspiration 26.65 25.64 24 10708 7064 3368063
Abscess drainage 26.54 25.64 8 10724 221 3374906
Deafness 26.53 25.64 19 10713 4035 3371092
Toxic skin eruption 26.53 25.64 17 10715 3011 3372116
Contusion 26.43 25.64 34 10698 14976 3360151
Prothrombin time prolonged 26.41 25.64 17 10715 3033 3372094
Coma 26.24 25.64 31 10701 12521 3362606
Cellulitis 26.20 25.64 31 10701 12544 3362583
Cachexia 26.12 25.64 13 10719 1418 3373709
Blood urine present 26.11 25.64 17 10715 3093 3372034
Lymphocytic infiltration 26.03 25.64 9 10723 388 3374739
Skin discolouration 26.00 25.64 23 10709 6613 3368514
Somnolence 25.98 25.64 51 10681 32153 3342974
Fibrosis 25.79 25.64 11 10721 842 3374285
Paraneoplastic syndrome 25.79 25.64 8 10724 244 3374883

Pharmacologic Action:

SourceCodeDescription
ATC L01XE01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Protein kinase inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent
FDA EPC N0000175605 Kinase Inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Dermatofibrosarcoma protuberans indication 276799004 DOID:3507
Systemic mast cell disease indication 397016004 DOID:349
Blastic phase chronic myeloid leukemia indication 413656006
Chronic eosinophilic leukemia indication 413836008
Chronic phase chronic myeloid leukemia indication 413847001
Gastrointestinal stromal tumor indication 420120006 DOID:9253
Idiopathic hypereosinophilic syndrome indication 423294001
Philadelphia chromosome-positive acute lymphoblastic leukemia indication 425688002
Myelodysplastic/ Myeloproliferative Diseases associated with Platelet-derived Growth Factor Receptor indication
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication
Chronic Myelocytic Leukemia Accelerated Phase indication
Heart valve disorder contraindication 368009 DOID:4079
Cerebral edema contraindication 2032001 DOID:4724
Hypophosphatemia contraindication 4996001
Congenital heart disease contraindication 13213009 DOID:1682
Hyperbilirubinemia contraindication 14783006 DOID:2741
Pulmonary edema contraindication 19242006 DOID:11396
Hypertensive disorder contraindication 38341003 DOID:10763
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Myocarditis contraindication 50920009 DOID:820
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:2527
Bleeding contraindication 131148009
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Pericardial effusion contraindication 373945007 DOID:118
Purpuric disorder contraindication 387778001 DOID:3326
Ascites contraindication 389026000
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Pleural Effusions contraindication
Chronic Heart Failure Following Myocardial Infarction contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.96 acidic
pKa2 8.49 Basic
pKa3 4.34 Basic
pKa4 3.73 Basic
pKa5 2.2 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** GLEEVEC NOVARTIS N021335 May 10, 2001 DISCN CAPSULE ORAL 6894051 May 23, 2019 A METHOD FOR TREATING A TUMOR DISEASE
EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** GLEEVEC NOVARTIS N021335 May 10, 2001 DISCN CAPSULE ORAL 6894051 May 23, 2019 A METHOD FOR TREATING A TUMOR DISEASE
EQ 100MG BASE GLEEVEC NOVARTIS N021588 April 18, 2003 RX TABLET ORAL 6894051 May 23, 2019 A METHOD FOR TREATING A TUMOR DISEASE
EQ 400MG BASE GLEEVEC NOVARTIS N021588 April 18, 2003 RX TABLET ORAL 6894051 May 23, 2019 A METHOD FOR TREATING A TUMOR DISEASE
EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** GLEEVEC NOVARTIS N021335 May 10, 2001 DISCN CAPSULE ORAL 6958335 Dec. 19, 2021 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** GLEEVEC NOVARTIS N021335 May 10, 2001 DISCN CAPSULE ORAL 6958335 Dec. 19, 2021 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
EQ 100MG BASE GLEEVEC NOVARTIS N021588 April 18, 2003 RX TABLET ORAL 6958335 Dec. 19, 2021 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
EQ 100MG BASE GLEEVEC NOVARTIS N021588 April 18, 2003 RX TABLET ORAL 6958335 Dec. 19, 2021 TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)
EQ 400MG BASE GLEEVEC NOVARTIS N021588 April 18, 2003 RX TABLET ORAL 6958335 Dec. 19, 2021 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
EQ 400MG BASE GLEEVEC NOVARTIS N021588 April 18, 2003 RX TABLET ORAL 6958335 Dec. 19, 2021 TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 100MG BASE GLEEVEC NOVARTIS N021588 April 18, 2003 RX TABLET ORAL Jan. 25, 2020 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH CHEMOTHERAPY, APPROVED UNDER NDA #21588/S-037
EQ 400MG BASE GLEEVEC NOVARTIS N021588 April 18, 2003 RX TABLET ORAL Jan. 25, 2020 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH CHEMOTHERAPY, APPROVED UNDER NDA #21588/S-037

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 7.89 CHEMBL CHEMBL
Tyrosine-protein kinase ABL1 Kinase INHIBITOR Kd 8.96 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.85 CHEMBL CHEMBL
Ephrin type-B receptor 4 Kinase Ki 5 PDSP
Cytoplasmic tyrosine-protein kinase BMX Kinase Ki 5 PDSP
Insulin receptor Kinase AGONIST Ki 5 PDSP
Tyrosine-protein kinase JAK2 Kinase Ki 5 PDSP
Sodium-dependent serotonin transporter Transporter Ki 6.13 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.27 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.71 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 6.70 DRUG MATRIX
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
Tyrosine-protein kinase Fgr Kinase Kd 5.62 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.51 CHEMBL
Solute carrier family 22 member 3 Transporter IC50 4.59 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 5.20 CHEMBL
Epidermal growth factor receptor Kinase Kd 5.12 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 7.52 CHEMBL
Multidrug resistance protein 1 Transporter IC50 5.14 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.28 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 4.59 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Ki 4.51 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.51 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 5.38 CHEMBL
Cyclin-G-associated kinase Kinase Kd 6 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 5.59 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 5.72 CHEMBL
Tyrosine-protein kinase SYK Kinase IC50 5.30 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 5.77 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 5.48 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 5.82 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.35 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 5.85 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 5.11 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 5.37 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 6.02 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 6.46 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 7.40 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 6.42 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 5.55 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 5.68 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 5.06 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.05 CHEMBL
Lysine--tRNA ligase Enzyme Ki 5.30 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 6.01 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 8.22 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 5.34 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.28 CHEMBL
Mitogen-activated protein kinase 8 Kinase Kd 5.49 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.51 CHEMBL
Tyrosine-protein kinase ABL Kinase IC50 7.40 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.96 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 7.82 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme IC50 6.40 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 9.15 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 7.40 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 6.28 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 4.69 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter IC50 5.47 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 6.33 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 6.96 CHEMBL
Bcr/Abl fusion protein Kinase Ki 7.85 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.12 CHEMBL
Cyclin-dependent kinase 19 Kinase Kd 5.26 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 7.50 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 4.77 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 6.41 CHEMBL
Platelet-derived growth factor receptor Kinase IC50 7.30 CHEMBL
Fibroblast growth factor receptor 2 Kinase Ki 5 PDSP
Mitogen-activated protein kinase 14 Kinase IC50 4.86 CHEMBL
Fibroblast growth factor receptor 1 Kinase Ki 5 PDSP
Ephrin type-B receptor 1 Kinase Ki 5 PDSP
Carbonic anhydrase 13 Enzyme Ki 5.13 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 5.56 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 7.97 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.11 CHEMBL

External reference:

IDSource
4021257 VUID
N0000148698 NUI
C0935989 UMLSCUI
5687 IUPHAR_LIGAND_ID
D01441 KEGG_DRUG
DB00619 DRUGBANK_ID
CHEMBL941 ChEMBL_ID
d04758 MMSL
282388 RXNORM
4021257 VANDF
391634008 SNOMEDCT_US
414460008 SNOMEDCT_US
N0000148698 NDFRT
009151 NDDF
8A1O1M485B UNII
220127-57-1 SECONDARY_CAS_RN
5291 PUBCHEM_CID
CHEMBL1642 ChEMBL_ID
8031 INN_ID
D000068877 MESH_DESCRIPTOR_UI
CHEBI:45783 CHEBI
STI PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0401 TABLET 100 mg ORAL NDA 18 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0438 TABLET 400 mg ORAL NDA 18 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0649 TABLET 400 mg ORAL NDA 18 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7629 TABLET, FILM COATED 100 mg ORAL ANDA 18 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7630 TABLET, FILM COATED 400 mg ORAL ANDA 18 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2245 TABLET, FILM COATED 100 mg ORAL ANDA 18 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2246 TABLET, FILM COATED 400 mg ORAL ANDA 18 sections
imatinib mesylate HUMAN PRESCRIPTION DRUG LABEL 1 16714-704 TABLET, FILM COATED 100 mg ORAL ANDA 18 sections
imatinib mesylate HUMAN PRESCRIPTION DRUG LABEL 1 16714-705 TABLET, FILM COATED 400 mg ORAL ANDA 18 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 42291-351 TABLET, FILM COATED 100 mg ORAL ANDA 18 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 42291-352 TABLET, FILM COATED 400 mg ORAL ANDA 18 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 42292-043 TABLET, FILM COATED 100 mg ORAL ANDA 18 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 42292-044 TABLET, FILM COATED 400 mg ORAL ANDA 18 sections
imatinib mesylate HUMAN PRESCRIPTION DRUG LABEL 1 47335-472 TABLET, FILM COATED 100 mg ORAL ANDA 18 sections
imatinib mesylate HUMAN PRESCRIPTION DRUG LABEL 1 47335-475 TABLET, FILM COATED 400 mg ORAL ANDA 18 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 50268-426 TABLET, FILM COATED 100 mg ORAL ANDA 19 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 50268-427 TABLET, FILM COATED 400 mg ORAL ANDA 19 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60429-925 TABLET, FILM COATED 100 mg ORAL ANDA 18 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60429-926 TABLET, FILM COATED 400 mg ORAL ANDA 18 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-2900 TABLET, FILM COATED 100 mg ORAL ANDA 18 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-2901 TABLET, FILM COATED 400 mg ORAL ANDA 18 sections
imatinib mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60687-192 TABLET, FILM COATED 100 mg ORAL ANDA 19 sections
imatinib mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60687-203 TABLET, FILM COATED 400 mg ORAL ANDA 19 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 69189-0403 TABLET 100 mg ORAL NDA 18 sections